FDA approves new treatment for secondary hyperparathyroidism

Image from pharmpro.com

Image from pharmpro.com

The US Food and Drug Administration has approved a new treatment for secondary hyperparathyroidism which is administered at the end of a dialysis session.  See the link below for the full story.

FDA approves new treatment for secondary hyperparathyroidism

Share

I’m an ADPKD patient who was lucky enough to have a transplant in 2003 after only eleven months of dialysis. I'm the north-west Patient Advocacy & Support Officer for Kidney Care UK and my interests, other than my role within GMKIN, include sport, music and politics. Follow me on Twitter: @finnigr

This entry was posted in . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *